Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose-escalation Strategy of Regorafenib in Patients With Advanced Hepatocellular Carcinoma

NCT05622136 is registered in ClinicalTrials.gov with Instituto do Cancer do Estado de São Paulo as lead sponsor.

NCT NCT05622136
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05622136 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose-escalation Strategy of Regorafenib in Patients With Advanced Hepatocellular Carcinoma
Lead sponsor
Instituto do Cancer do Estado de São Paulo
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 10, 2023
Completion date
December 15, 2026
Enrollment
28 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, liver cancer